- Home
- EMD vs PRTA Comparison
EMD vs PRTA Comparison
Compare EMD & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | PRTA |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.9M | 538.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EMD | PRTA |
|---|---|---|
| Price | $11.02 | $8.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 248.5K | ★ 490.1K |
| Earning Date | 01-01-0001 | 02-19-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,183.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.85 | $4.32 |
| 52 Week High | $9.55 | $16.67 |
Technical Indicators
Market Signals| Indicator | EMD | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 44.64 |
| Support Level | $10.86 | $8.23 |
| Resistance Level | $11.06 | $9.05 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 93.94 | 28.26 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.